Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Change in Accured Expenses (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Change in Accured Expenses data on record, last reported at $4.5 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 201.01% year-over-year to $4.5 million; the TTM value through Dec 2025 reached $1.1 million, down 2.65%, while the annual FY2025 figure was $1.1 million, 2.65% down from the prior year.
  • Change in Accured Expenses reached $4.5 million in Q4 2025 per TNGX's latest filing, up from $1.6 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $4.5 million in Q4 2025 and bottomed at -$6.7 million in Q1 2023.
  • Average Change in Accured Expenses over 5 years is $583350.0, with a median of $1.3 million recorded in 2024.
  • Peak YoY movement for Change in Accured Expenses: soared 88020.16% in 2021, then plummeted 4169.43% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at $35000.0 in 2021, then skyrocketed by 4985.71% to $1.8 million in 2022, then soared by 124.55% to $4.0 million in 2023, then crashed by 62.7% to $1.5 million in 2024, then surged by 201.01% to $4.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $4.5 million in Q4 2025, $1.6 million in Q3 2025, and $1.1 million in Q2 2025.